BETA - Pilot Study

Prior treatment

• History of severe hypoglycemia or diabetes-related ketoacidosis in the prior 6 months or \>2 episodes in the past 12 months.

Other illness

• Allergy to dairy or soy
• History of pancreatic disease (other than diabetes) or pancreatic transplantation
• Active malignancy or chemotherapy for malignancy within the past year

Lab values

• History of bariatric surgery or other gastrointestinal surgery anticipated to affect glucose metabolism, or any cause of gastroparesis
• Renal, hepatic, cardiovascular, or other systemic disease likely to interfere with glucose metabolism or study participation.
• Current use of the following medications: Calcium channel blockers (e.g., verapamil), glucocorticoids, non-selective beta blockers (e.g., propranolol), GLP-1 receptor agonists, SGLT inhibitors, DPP-4 inhibitors, sulfonylureas, meglitinides, metformin, or thiazolidinediones.

Other

• Pregnant or breastfeeding
• Current tobacco use
• Overnight hospitalization for any reason in the past 3 months.

• 18 years of age or older
• An established diagnosis of Type 1 diabetes
• Self-reported glycated hemoglobin (HbA1c) below 8% (64 mmol/mol)
• Body Mass Index 18-40 kg/m2
• Fluent in written and spoken English
• Own a personal iPhone 6s or later (iOS 15+ or newer) or Android smartphone (version 12 or newer) and willing to use this phone to download and use the app for the study
• Own a personal Dexcom CGM and willing to provide the study researchers access to it's data during the study.
• Willing to use the study wearable devices (Oura ring, Empatica wristband)
• Resides in the San Francisco Bay area and willing to travel to Novato, CA on at least two occasions for the in person assessments at the Buck Institute.
• If using long-acting insulin (e.g. Basaglar, Lantus, Levemir, Toujeo, Tresiba), must be on a dosing schedule that involves administration of insulin only at bedtime and no other times of day
• Willing to stop use of prescription or over-the-counter medications containing acetaminophen (e.g. Tylenol, Percocet, Nyquil and other common medications for cold and flu, etc.) due to potential interference with the study-provided continuous glucose monitor.